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Abstract
There is public concern over the long term systemic health effects of metal released from hip replacement prostheses that
use large-diameter metal-on-metal bearings. However, to date there has been no systematic study to determine which
organs may be at risk, or the magnitude of any effect. We undertook a detailed cross-sectional health screen at a mean of 8
years after surgery in 35 asymptomatic patients who had previously received a metal-on-metal hip resurfacing (MoMHR)
versus 35 individually age and sex matched asymptomatic patients who had received a conventional hip replacement. Total
body bone mineral density was 5% higher (mean difference 0.05 g/cm2, P = 0.02) and bone turnover was 14% lower (TRAP
5b, mean difference 20.56IU/L, P = 0.006; osteocalcin, mean difference 23.08 ng/mL, P = 0.03) in the hip resurfacing versus
conventional hip replacement group. Cardiac ejection fraction was 7% lower (mean absolute difference 25%, P = 0.04) and
left ventricular end-diastolic diameter was 6% larger (mean difference 2.7 mm, P = 0.007) in the hip resurfacing group versus
those patients who received a conventional hip replacement. The urinary fractional excretion of metal was low (cobalt 5%,
chromium 1.5%) in patients with MoMHR, but creatinine clearance was normal. Diuretic prescription was associated with a
40% increase in the fractional excretion of chromium (mean difference 0.5%, P = 0.03). There was no evidence of difference
in neuropsychological, renal tubular, hepatic or endocrine function between groups (P.0.05). Our findings of differences in
bone and cardiac function between patient groups suggest that chronic exposure to low elevated metal concentrations in
patients with well-functioning MoMHR prostheses may have systemic effects. Long-term epidemiological studies in patients
with well-functioning metal on metal hip prostheses should include musculoskeletal and cardiac endpoints to quantitate
the risk of clinical disease.
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Introduction
There is public concern about the potential systemic health
effects of metal exposure in patients who have received large
diameter ($36 mm) metal-on-metal hip prostheses [1], however
there is little data available to quantitate which systems may be
affected or the magnitude of any effect [2]. The Food and Drug
Administration (FDA) in the United States has recently (May 6th,
2012) instructed manufacturers of large diameter metal-on-metal
hip prostheses to conduct cross-sectional studies covering the
period from implantation out to 8 years after surgery in order to
quantitate the adverse local and systemic effects of metal exposure
from these devices (http://www.fda.gov/MedicalDevices/Safety/
AlertsandNotices/ucm335775.htm, accessed May 13th, 2013).
The FDA has also advised physicians that asymptomatic patients
at risk of increased metal release and symptomatic patients should
be clinically monitored for cardiovascular, neurological, renal, and
thyroid signs and symptoms (http://www.fda.gov/MedicalDevices/
ProductsandMedicalProcedures/ImplantsandProsthetics/Metalon
MetalHipImplants/ucm241667.htm, accessed May13th, 2013).
Cobalt and chromium are the principal metals released by metal-
on-metal hip prostheses [3,4], including metal-on-metal hip
resurfacing (MoMHR). The evidence base for the FDA recom-
mendations in relation to systemic disease derives from case reports
of grossly elevated metal levels associated with mal-functioning
prostheses, or is translated from their toxicology in animal studies,
and accidental or occupational over-exposure in humans
[5,6,7,8,9].
It is estimated that world-wide approximately 1 million patients
have received a hip replacement that uses a large-diameter metal-
on-metal bearing, and the majority of these patients have well-
functioning devices [10]. Well-functioning prostheses also release
metal species into the systemic circulation over a prolonged period
after surgery. Steady state median blood cobalt and chromium
concentrations over 10 years in patients with well-functioning
devices are between 1.5 and 2.3 mg/L, and are 10-fold higher than
normal physiological concentrations [11,12]. The systemic effects
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of this prolonged exposure to low elevated metal levels is unknown
and, to date, unstudied [2]. We have recently shown that
concentrations of cobalt and chromium equivalent to blood levels
after MoMHR affect human bone cell viability and function in-
vitro [13]. Further, Linna et al [14], found cobalt workers exposed
to a blood cobalt level of 2.5 mg/L over 9 years had echocardio-
graphic evidence of altered left ventricular function versus
unexposed controls.
Direct evidence for effects of chronic exposure to metal on
systemic organ function in patients with well-functioning implants
is needed to inform appropriate endpoints for the studies now
required of manufacturers, and to inform the appropriate clinical
monitoring of patients. We conducted a cross-sectional, in-depth,
systematic health screen in patients with well-functioning
MoMHR 8 years after implantation and an individually-matched
group of patients who received a conventional total hip
arthroplasty (THA) in order to determine which organ systems
may be susceptible to altered function following insertion of these
implants.
Patients and Methods
Ethics, design, setting, and participants
We undertook this single-centre cross-sectional study at a
teaching hospital in Sheffield, United Kingdom. Patients were
recruited from the community between November 24th, 2009 and
May 20th, 2010. The study was approved by South Yorkshire
Research Ethics Committee, and all patients provided written
informed consent prior to participation. The study design was
reviewed by a statistician at Sheffield Clinical Trials Research
Unit, and its conduct and dissemination of results were reviewed
by Sheffield Lay Advisory Panel for Bone Research.
The MoMHR exposure patients comprised individuals who had
undergone surgery for osteoarthritis not less than 5 years
previously. The non-exposure group comprised individually-
matched osteoarthritis patients who had received a conventional
THA using a non-metal-on-metal bearing. All patients were
recruited from the operating records of a single surgeon. The
MoMHR participants were identified first and individually-
matched THA participants were then identified from the same
surgeons operating records using the following matching criteria:
Age (within 3 years), gender, and time since hip surgery (within 2
years). The exclusion criteria were any revision surgery for
complications of hip arthroplasty, known inflammatory arthrop-
athy or metabolic bone disease, use of pharmacological doses of
estrogen, progestin, androgen, calcitonin, glucocorticoids, or
dietary supplements of calcium or vitamin D within the previous
12 months, any previous use of bisphosphonate or fluoride
therapy, pregnancy, and those patients in whom magnetic
resonance imaging (MRI) was contra-indicated.
Figure 1. Recruitment flow chart. MoMHR = metal-on-metal hip resurfacing, THA = conventional hip replacement using a non-metal-on-metal
bearing.
doi:10.1371/journal.pone.0066186.g001
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Blood, plasma, and urinary cobalt and chromium were
measured by inductively-coupled plasma-mass spectroscopy
(ICP-MS). Blood samples were collected via plastic cannula using
the last draw method directly into trace element collection tubes.
Metal assays were performed by two independent laboratories that
participate in National trace element measurement quality
assurance schemes. The mean value of the two laboratories was
used for analyses to reduce bias arising from inter-laboratory
measurement variability. Serum protein and iron status were also
quantitated to identify potential bias between study groups due to
trace metal bioavailability.
Outcomes
Total body bone mineral density (TB-BMD) and body
composition were measured by dual energy x-ray absorptiometry
using an Hologic Acclaim fan-beam densitometer (Hologic Inc,
Bedford, MA) with manual exclusion of regions containing
metallic prostheses from the analysis. Biochemical markers of
bone turnover were measured by automated electro-chemilumi-
nescent assay or by manual enzyme-linked immunosorbent assay
in fasting morning serum or 24-hour urine samples, and according
to manufacturer’s instructions. Cardiac function was assessed
using the New York Heart Association (NYHA) functional
classification for cardiac failure and by trans-thoracic echocardi-
ography in accordance with guidelines set by the British Society of
Echocardiographers. All examinations were made using the same
GE Vivid 7 ultrasound machine (GE Healthcare, Freiberg,
Germany). Twelve-lead electrocardiography was used to identify
conduction defects using a MAC 5500 resting ECG analysis
system (GE Healthcare).
Pre-morbid IQ was measured using the Wechsler test of adult
reading (WTAR) and the Hospital Anxiety and Depression scale
was administrated to test for any significant differences in these
influential variables between the groups. A battery of standardized
neuropsychological tests was performed, including: verbal learning
by California verbal learning test (CVLT-II); construction skills
and recall of visual information using the adult memory and
information processing battery (AMIPB) complex figure; spatial
perception using the line orientation test from the repeatable
battery for the assessment of neuropsychological status (RBANS);
attention and working memory using the digit-span subtest of the
Wechsler Adult Intelligence Scale (WAIS-III); psychomotor speed
using the digit symbol coding and digit symbol search subtests of
WAIS-III; verbal fluency using timed word naming for both
phonemic and semantic domains.
Renal function was measured by serum and urinary chemistry,
and creatinine clearance was calculated using the Mosteller
formula [15]. Renal injury was quantitated by manual immuno-
assay of urinary renal tubular enzymes previously shown to be
elevated in chronic kidney injury [16]. Urinary KIM-1, NAG, and
NGAL were measured from 24-hour urine collection by quanti-
tative sandwich enzyme immunoassay (NGAL and KIM-1, R+D
Systems, Minneapolis, MN, USA; NAG, USCN Life Sciences
Inc., Wuhan, China). Urinary fractional excretion of metal relative
to creatinine was also calculated. Hepatic function, injury, and
metal accumulation were assessed by liver function tests,
coagulation screen, fasting lipid profile, and by gradient echo
Table 1. Patient characteristics and metal levels.
Characteristic MoMHR (n = 35) THA (n = 35)
Age at surgery (years) 51.266.6 51.868.2
Gender (M:F) 31:4 31:4
Time since surgery (years) 8.161.8 7.862.4
Bilateral: Unilateral hip replacement 11:24 12:23
Bearing diameter (mm) 50 (46 to 52) 28 (22 to 28)
Height (m) 1.74 (0.07) 1.72 (0.08)
Weight (Kg) 86.5 (17.4) 84.9 (15.9)
Body mass index (Kgm22) 28.6 (4.7) 28.4 (3.6)
Fat mass (Kg) 21.2 (9.1) 22.2 (6.9)
Lean mass (kg) 60.969.9 58.4611.1
Body fat (%) 25.166.3 27.365.6
Body surface area (m2) 2.04 (0.23) 2.01 (0.23)
Oxford hip score 46 (43 to 48) 46 (40 to 48)
EQ-5D 1.0 (0.7 to 1.0) 0.9 (0.7 to 1.0)
EQ-VAS 84.7 (11.2) 81.5 (16.7)
‘FRAX’ 10-year major osteoporotic fracture risk (%) 4.7 (2.1) 4.2 (1.5)
*Whole blood cobalt (mg/L) 1.75 (1.11 to 6.11) 0.38 (0.33 to 0.55)
*Whole blood chromium (mg/L) 1.27 (1.04 to 3.91) ,0.30 (,0.30 to ,0.30)
*Plasma cobalt (mg/L) 1.48 (0.90 to 5.62) ,0.30 (,0.30 to ,0.30)
*Plasma chromium (mg/L) 2.51 (1.61 to 7.07) ,0.30 (,0.30 to 0.31)
*Urinary cobalt (mg/L) 7.47 (4.13 to 17.47) ,0.30 (,0.30 to ,0.30)
*Urinary chromium (mg/L) 3.12 (1.54 to 7.23) ,0.30 (,0.30 to ,0.30)
Normally distributed data are presented as mean 6SD, and non-normally distributed data as median (IQR). Analysis is MoMHR versus THA. Continuous data were
analyzed by paired t-test or Wilcoxon test; categorical data were analyzed by either Chi-squared test. *P,0.0001, P.0.05 for all other comparisons.
doi:10.1371/journal.pone.0066186.t001
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T2* weighted MRI with varying echo time of the liver and spleen,
respectively. All MRI examinations were made using the same 3.0
Tesla Philips MRI scanner (Philips Intera, Best, Netherlands).
Endocrine function was evaluated by serum assay of hypothalamo-
pituitary axis hormones and pituitary volume was measured by
MRI. Insulin resistance was measured by serum assay of fasting
glucose and insulin and expressed as the glucose to insulin ratio
[17].
Statistical analysis
The study was powered for the primary outcome measure of
TB-BMD. For a population mean TB-BMD of 0.80 g/cm2
(standard deviation 0.06 g/cm2) a sample size of 35 patients per
group had 80% power to detect a 5% difference in TB-BMD
between patient groups, assuming a within-pair correlation of 0.6
and using a 2-tailed paired t-test with an alpha of 0.05. All
between-group analyses of continuous data were conducted using
the paired t-test, or the Wilcoxon test, where appropriate, and
categorical data were analysed using the chi-squared test.
Results
Participants and metal levels
Between November 2009 and May 2010, 203 (83 with
MoMHR and 120 with THA) potentially eligible patients were
invited to participate (Figure 1). We received no response or a
decline from 32 of the MOMHR patients and 56 of the THA
patients. In the MoMHR group a further 15 patients were
excluded for the following reasons: contra-indication to MRI
(n = 3), inflammatory arthropathy or metabolic bone disease
(n = 3), recent arthroplasty to other joints (n = 3), MoMHR
revision (n = 1), use of calcium dietary supplements (n = 2), and
current illness (n = 3). In the THA group 28 patients were
excluded for the following reasons: complications or revision of the
prosthesis (n = 10), failure of the matching criteria (n = 7),
inflammatory arthropathy or metabolic bone disease (n = 3),
glucocorticoid treatment (n = 3), contra-indication to MRI
(n = 3), recent arthroplasty to other joints (n = 1) and subject
withdrawal (n = 1). One further patient from each group was
excluded after enrolment for screening failure (1 for cancer and the
other for an intra-orbital foreign body that precluded MRI
investigation). The age distribution of those patients invited to
participate but were not enrolled was similar to those who
participated (age 6061years versus 5961 in recruits, P = 0.53),
although a greater proportion were female (M:F = 98:33 versus
62:8 in recruits; P = 0.02).
Thirty-five pairs of age, gender and time since surgery matched
patients completed the study (Table 1). The patients in both
groups were also well-matched for body composition, general
health measured by EQ-5D and EQ-VAS, Oxford hip score, and
pre-arthroplasty risk of osteoporotic fracture by FRAX score. In
the MoMHR group 32 patients had received the Birmingham hip
resurfacing prosthesis (Smith & Nephew Inc., Andover, MA; FDA
approved 2006) and 3 the ASR prosthesis (DePuy Inc., Warsaw,
IN; not FDA approved). In the THA group 17 patients received a
metal-on-polyethylene bearing, 17 received a ceramic-on-ceramic
bearing, and in one a ceramic-on-polyethylene bearing. Median
blood, plasma, and urinary cobalt and chromium were 5 to 50 fold
higher in MoMHR versus THA patients (P,0.0001). However,
blood median and interquartile range metal levels were below
guidance threshold concentration of .7 mg/L suggestive of
prosthesis mal-function, and set by the Medicines and Healthcare
Products Regulatory Agency (MHRA) in the United Kingdom
(update MDA/2012/036; 25 June 2012). In the THA group
blood, plasma and urinary cobalt concentrations were below the
ICP-MS detection limit of 0.3 mg/L in 6, 24, and 27 of the 35
patients, respectively; and chromium concentrations were below
this limit in 21, 12, and 22 patients, respectively.
Outcomes
TB-BMD was 5% higher in the MoMHR versus the THA
group (Figure 2a: 1.04 g/cm2 versus 1.00 g/cm2, mean difference
0.05 g/cm2; 95% confidence interval 0.01 to 0.09: P = 0.02).
Within the appendicular skeleton (upper limb), BMD was 4%
higher in the MoMHR versus the THA group (0.86 g/cm2 versus
0.83 g/cm2, mean difference 0.03 g/cm2; 0.01 to 0.06: P = 0.02).
Within the axial skeleton (spine and ribs), BMD was 5% higher in
the MoMHR versus THA group (0.83 versus 0.79, mean
difference 0.04 g/cm2; 0.00 to 0.08: P = 0.08). Bone formation,
Figure 2. Bone endpoints in MoMHR versus THA patients. A)
Mean difference in bone mineral density at various body sites, and B)
differences in bone turnover markers between the patient groups.
TRAP-5b = Tartrate-resistant acid phosphatase 5b, CTX-I = C-telopep-
tide of type I collagen, OC = osteocalcin, PINP = N-terminal propeptide
of type-I procollagen, BAP = bone-specific alkaline phosphatase.
Comparison is the difference in endpoint in MoMHR versus THA
patients by paired t-test.
doi:10.1371/journal.pone.0066186.g002
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measured by serum osteocalcin was 14% lower (mean difference
23.08 ng/mL; 25.83 to 20.33: P = 0.03) and osteoclast number
measured by serum tartrate-resistant acid phosphatase 5b was
14% lower (mean difference 20.56IU/L; 20.96 to 20.17:
P = 0.006) in the MoMHR patients versus the THA group (Figure
2b).
Patients in both groups had similar levels of risk factors for heart
disease, treatment, cardiac symptoms by NYHA score, resting
heart rate, and evidence of conduction abnormalities by ECG
(Table 2, P.0.05, all comparisons). Trans-thoracic echocardiog-
raphy demonstrated that cardiac ejection fraction was 7% lower
(Table 2; 60% versus 65%; mean absolute difference 25%; 95%
CI 29.4 to 20.19: P = 0?04) and left ventricular end-diastolic
diameter was 6% larger (48.9 mm versus 46.2 mm, mean
difference 2.7 mm; 0.80 to 4.57: P = 0.007) in the MoMHR
versus the THA patients.
Patients in the MoMHR group had similar levels of neuropsy-
chological function measured using standardized tests of cognitive,
behavioural, and psychological function versus patients in the
THA group (P.0.05, Table 3). Hospital anxiety and depression
scores were also similar between the groups (P.0.05). Serum
electrolytes, creatinine clearance, and enzymatic markers of renal
tubular damage were similar between groups (Table 4; P.0.05, all
comparisons). In the MoMHR group daily urinary excretion of
cobalt versus chromium was 12.2 mg (interquartile range 8.6 to
45.6) versus 6?2 mg (4.0 to 18.5, P,0.0001). The fractional
excretion of cobalt (relative to creatinine) versus chromium was
5% versus 1% (Figure 3, P,0.0001). The fractional excretion of
both metals was constant and independent of plasma metal
concentration (gradient of slope = zero, P.0.05). Five of the 35
subjects in the MoMHR group were prescribed diuretics. Urinary
fractional excretion of chromium in this sub-group was 40%
higher than in the non-users (mean difference 0.5%, 0.1 to 1.0;
P = 0.03). Urinary metal levels were undetectable in the majority
of patients in the THA group, precluding estimation of daily and
fractional metal excretion.
Serum markers of liver synthetic function and injury, fasting
lipids, and clotting factors were similar between groups (Table 4;
P.0.05). Serum protein, albumin, ferritin and transferrin receptor
concentrations, which may affect biological availability of metal,
Table 2. Cardiac endpoints.
Characteristic MoMHR (n = 35) THA (n = 35)
Alcohol (units/week) 14.6 (15.9) 17.1 (14.7)
Smoking: (never/current/Ex. 5years/Ex.,5 years) 22/4/2/7 23/3/1/8
Treated or known hypertension 6 11
History of diabetes mellitus 3 3
Cholesterol (mmol/L) 5.161.1 5.361.3
Triglyceride (mmol/L) 1.360.8 1.460.9
High density lipoprotein cholesterol (mmol/L) 1.260.4 1.260.4
Low density lipoprotein cholesterol (mmol/L) 3.360.9 3.461.1
Total/high density lipoprotein cholesterol ratio 4.461.4 4.661.7
Statin treatment 7 12
History of ischaemic heart disease 2 0
NYHA cardiac failure score 1 (1 to 1) 1 (1 to 1)
Conduction defect identified by ECG 3 2
Resting heart rate 63612 6269
Left ventricular end-diastolic diameter (mm)** 4964 4664
End systolic diameter (mm) 3166 2964
Iinterventricular septum thickness(mm) 1162 1162
Posterior wall thickness (mm) 1161 1062
Ejection fraction (%)* 6069 6567
Normally distributed data are presented as mean 6SD, and non-normally distributed data as median (IQR). Analysis is MoMHR versus THA. Continuous data were
analyzed by paired t-test or Wilcoxon test; categorical data were analyzed by either Chi-squared test. *P,0.05, **P,0.01, P.0.05 for all other comparisons.
doi:10.1371/journal.pone.0066186.t002
Figure 3. Urinary fractional excretion of cobalt and chromium
versus plasma metal level in MoMHR patients. Line represents
regression slope and dotted line represents 95% confidence interval.
Comparison is fractional excretion of cobalt versus fractional excretion
of chromium by linear regression analysis (P,0.0001).
doi:10.1371/journal.pone.0066186.g003
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were also similar between groups (P.0.05). Patients in the
MoMHR group had increased magnetic resonance T2* relaxa-
tion-time for the liver (mean difference 0.94msec; 0.09 to 1.79:
P = 0.03) and spleen (mean difference 0.87msec; 0.05 to 1.68:
P = 0.04) versus THA patients, consistent with metal deposition
within these organs. Eleven patients (7 MoMHR and 4 THA) did
not complete the MRI protocol for liver imaging due to MRI
scanner intolerance. Circulating hypothalamo-pituitary axis and
downstream hormones and pituitary volume were similar between
groups (Table 3, P.0.05). Fasting serum glucose, insulin and
glucose to insulin ratio were also similar between groups (P.0.05).
Discussion
We conducted an in-depth cross-sectional health screen to
identify those organ systems that may be susceptible to chronic
metal exposure at levels representative of patients with well-
functioning MoMHR devices to inform clinical monitoring
guidelines and the design of larger scale screening studies now
required of prosthesis manufacturers. Our data suggest mixed
health effects, including potentially positive effects on systemic
bone mass, but potentially deleterious effects on left ventricular
function. Our data suggest that the cross-sectional study designs
required of manufacturers by the FDA, and the clinical follow-up
of asymptomatic patients with elevated metal levels, should
prioritize these organ systems. In contrast, we found no evidence
to implicate neuropsychological, psychological, renal, or endocrine
dysfunction at this level of metal exposure. We also found no
evidence of association between metal exposure and hepatic
dysfunction, although we did find MRI signal in the liver and
spleen consistent with metal deposition. Our data also suggest that
the FDA-required studies should include data collection on
concurrent medication that may modulate the urinary fractional
excretion of chromium or cobalt.
This study was conducted in a clinically healthy population and
the patients underwent a high level of investigational phenotyping.
The MoMHR patients studied showed good external validity to
the general MoMHR population as they reflected the younger
arthroplasty patient, and the majority were male. The study also
reflected well-functioning devices, as the majority of prostheses
were of the Birmingham design, most subjects had an Oxford hip
score greater than 42 that defines an excellent outcome, and they
had a blood metal concentration that was below the MHRA 7 mg/
L threshold. Levels of both cobalt and chromium in blood in
normal health are typically #0.30 m/L (4 nmol/L) [18]. Blood
metal concentrations rise after MoMHR insertion, and usually
peak during the first year after surgery at 1.3 to 2.5 m/L [18,19].
In the long term after surgery metal levels remain elevated above
physiological levels in well-functioning implants, with mean levels
at between 0.8 and 2.5 mg/L in well-functioning implants up to 10
years after surgery [18,20,21]. Local tissue levels at the site of the
prosthesis are higher. Kwon et al reported cobalt and chromium
levels within the hip joint synovial fluid of patient with well-
functioning implants of 1 to 158 mg/L and 3 to 230 mg/L,
respectively [22]. Cobalt and chromium levels in the synovial fluid
of patients with failing prostheses may reach 24,000 mg/L and
263,000 mg/L, respectively,_ENREF_10 and blood metal can
reach several hundred or thousands of mg/L [23,24,25].
These clinical findings confirm clinically our previous observa-
tions in-vitro that cobalt and chromium concentrations within the
relevant systemic range after MoMHR may affect systemic bone
cell function [13]. One explanation for this observation is that
chronic metal exposure after MoMHR has a direct systemic anti-
resorptive effect on bone through suppression of osteoclast number
or activity, resulting in increased secondary mineralization of bone
in a similar manner to that seen with bisphosphonate therapy [26].
This mechanism is supported by the lower TRAP-5b levels in the
MOMHR patients, suggesting reduced osteoclast number. The
effect might also be exerted through an indirect mechanism, as
chromium increases insulin sensitivity [27], modulating the
anabolic skeletal effects of both insulin and parathyroid hormone
[28,29]. However, our glucose and insulin assay data suggests that
Table 3. Neuropsychological and psychological endpoints.
Test variable MoMHR (n = 35) THA (n = 35)
Construction skills by copy (%) 9765 9763
Immediate recall of visual information (%) 74616 69615
Delayed recall of visual information (%) 73615 68616
Retained recall of visual information (%) 100612 9969
Spatial perception by Line Orientation (number correct) 1962 1862
Verbal Learning (total correct over trials 1 to 5) 62612 64611
Psychomotor speed (sum of scaled scores) 2064 2165
Attention and working memory (number of forward digits correct) 761 761
Attention and working memory (number of backward digits correct) 562 561
Attention and working memory (difference between forwards and backwards span) 261 261
Verbal fluency- semantic (number of animals listed in 60 seconds) 1964 2064
Verbal fluency- phonetic (sum of number of words listed beginning with each of F, A and S
in 60 seconds)
40613 41611
Pre-morbid Intelligence Quotient (full scale scored IQ calculated using United Kingdom
normative data)
99610 10169
Hospital anxiety score 4 (3 to 6) 4 (2 to 8)
Hospital depression score 3 (2 to 6) 2 (1 to 6)
All test results were adjusted for by pre-morbid Intelligence Quotient using the Wechsler test for adult reading (WTAR). Values are mean6standard deviation or median
(interquartile range). Analysis is MoMHR versus THA by paired t-test or Wilcoxon test; P.0.05, all comparisons.
doi:10.1371/journal.pone.0066186.t003
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there was no overt difference in insulin sensitivity between the
patient groups. An alternate explanation for our finding is that
metal deposition within bone artifactually raises the measured x-
ray attenuation. This effect is seen after strontium ranelate therapy
because the atomic weight of strontium that is twice that of
calcium [30]. However, both cobalt and chromium have atomic
weights that are similar to calcium, and thus are unlikely to have a
significant impact on x-ray attenuation or BMD measurements in
this study.
An association between cobalt exposure and cardiomyopathy
was first identified following its addition to beer as a foam-
stabilizing agent in Quebec in the 1960’s [31]. Linna et al have
previously shown that cobalt-workers had echocardiographic
evidence of altered left ventricular relaxation and early filling
versus unexposed controls [14]. The cobalt exposed workers in this
study had mean blood cobalt levels of 2.5 mg/L and a mean
duration of exposure of 8 years, that are similar to the exposure in
the MoMHR population studied here. Our findings of differences
in cardiac function are consistent with previous studies showing an
association between accidental or occupational cobalt exposure
and cardiomyopathy, although the differences in function we
found between patient groups was subtle. There were no patients
in either group with overt clinical cardiomyopathy by NYHA
class, and only 1 patient in the MOMHR group had an LVEDD
that exceeded the 56 mm upper limit of our normal reference
Table 4. Serum markers of renal, hepatic, and endocrine function and injury.
Serum analyte MoMHR (n = 35) THA (n = 35)
Renal function and injury
Sodium (mmol/L) 144.562.7 144.362.8
Potassium (mmol/L) 4.5 60.4 4.560.3
Urea (mmol/L) 5.661.9 5.161.1
Creatinine (mmol/L) 91.2620.0 88.6618.3
Creatinine clearance (mL/min/1.73 m2) 111.6635.3 99.1628.0
`Kidney injury molecule-1 (ng/mL) 0.760.5 0.860.1
`N-acetyl-b-(D)-glucosamidase (ng/mL) 25.2613.4 26.3616.7
`Neutrophil gelatinase-associated lipocalin (ng/mL) 2.9 (1.8 to 4.7) 2.9 (1.8 to 3.8)
Hepatic function and injury
Total protein (g/L) 71.763.8 73.564.8
Albumin (g/L) 44.662.3 45.163.3
Globulin (g/L) 27.163.7 28.463.0
Serum ferritin (mg/L) 174.16134.0 193.16137.4
Serum transferrin receptor 2.660.4 2.660.4
Adjusted calcium (mmol/L) 2.360.1 2.460.1
Total bilirubin (mmol/L) 13.4 67.8 12.466.1
Alkaline phosphatase (IU/L) 61.7615.3 63.3615.6
Alanine transaminase (IU/L) 31.769.6 29.7610.4
Prothrombin time (seconds) 10.660.7 10.660.4
Activated partial thromboplastin time (seconds) 30.963.0 31.763.7
Fibrinogen (g/L) 3.360.8 3.460.7
Endocrine function
Thyroid stimulating hormone (mIU/L) 2.3 61.4 2.261.2
Free tri-iodothyronine (pmol/L) 5.460.6 5.460.6
Luteinising hormione (IU/L) 4.8 (3.5 to 12.4) 4.8 (3.5 to 8.8)
Follicle stimulating hormone (IU/L) 6.1 (4.6 to 21.8) 6.4 (4.4 to 12.4)
Prolactin (mIU/L) 145.5664.3 153.2693.0
Cortisol (nmol/L) 423.76136.7 397.96107.7
`Testosterone (nmol/L) 15.366.3 14.265.7
Oestradiol (mIU/L) 35.469.5 31.5612.9
Growth hormone (mg/L) 0.4 (0.1 to 0.8) 0.40 (0.1 to 1.0)
Fasting insulin (mIU/L) 11.166.3 10.266.0
Fasting glucose (mmol/L) 6.261.0 5.961.1
Fasting glucose to insulin ratio (mmol/mIU) 0.860.5 0.960.9
Values are mean 6 standard deviation or median (interquartile range). Analysis is MoMHR versus THA by paired-t test or Wilcoxon test. P.0.05 all comparisons. `Marker
assayed in men only (n = 31 per group).
doi:10.1371/journal.pone.0066186.t004
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range. Similarly, the lower limit of our EF% reference range
(,50%) was exceeded by 2 patients in each study group.
The kidney is the primary route of excretion for metals, and
thus is a potential site for toxicity as metal is concentrated at this
site. Acute tubular necrosis, renal failure and chronic interstitial
nephritis are reported following accidental ingestion of chromic
acid [32]. In this study we found no evidence of renal injury using
sensitive markers of renal tubular damage applied for the first time
to the setting of MoMHR. Our finding of a clear difference in
fractional excretion of cobalt versus chromium, and a potential
interaction with diuretic therapy, requires further investigation
and may have relevance for potential long-term relative accumu-
lation of each metal. Cobalt inhibits tyrosine iodinase and
prolonged exposure can result in thyroid hyperplasia and
hypothyroidism [33]. Prolonged excess ingestion of chromium
results in its deposition in the anterior pituitary and endocrine
dysfunction, and increases insulin sensitivity [34]. The results of
our studies suggest that at exposure concentrations found after
successful MoMHR is not associated with endocrine dysfunction
of the hypothalamo-pituitary axis hormones, including thyroid
function, or alteration in pancreatic islet function.
The limitations of this study include potential pre-arthroplasty
systematic differences between the populations associated with
lifestyle choices, and potential differences in post-operative
function associated with each device. In mitigation of the former,
we found no evidence of systematic bias between groups to suggest
differences in physical function that might suggest a pre-operative
difference in BMD. Both groups had similar body mass index, lean
mass, percentage fat mass, resting heart rates, and physical
function by Oxford hip score. The groups also had similar pre-
morbid 10-year fracture probabilities by FRAX, indicating similar
risk factors for osteoporosis. Whilst unidentified differences in
activity levels or other aspects of general health could be the cause
of the difference in BMD, rather than effect of metal exposure, this
does not adequately explain the associated suppression of bone
turnover markers, and would be inconsistent with the observed
poorer cardiac function in the MoMHR group. In relation to the
second limitation, recent randomized clinical trial data indicates
that hip resurfacing does not confer better physical functional or
higher activity levels versus conventional arthroplasty in patients
with arthritis [35,36].
In conclusion, our data indicates that hip resurfacing associates
with subtle structural or functional differences in multiple solid
organs at 8 years after surgery in asymptomatic patients with well-
functioning MoMHR versus those who received conventional
THA. Our data suggest that long-term epidemiological studies in
large populations, such as those available through joint registries,
are required to quantitate the risk of clinical disease, and that these
studies should include cardiac and musculoskeletal endpoints.
Finally, our data suggest that the studies required of manufacturers
by the FDA should be conducted over an extended period if the
late clinical consequences of metal exposure are to be accurately
quantitated.
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